ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
126.526,27
1,51%
S&P 500
5.099,96
1,02%
US Dollar vs BRL
5,17208
1,09%
Bitcoin
62.777,33
-1,51%
Brent Oil
88,165
0,00%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Arcutis Biotherapeutics Inc (ARQT)

  7. Arcutis Biotherapeutics Inc (ARQT) Notícias

ARQT Arcutis Biotherapeutics Inc

8,31
-0,28 (-3,26%)
26 Abr 2024 - Fechado
Atrasado em 15 minutos
Nome da Ação Código da Ação Bolsa de Valores Tipo de Ativo
Arcutis Biotherapeutics Inc ARQT NASDAQ Ordinária
  Variação do Dia (p) Variação do Dia % Último Preço Hora
Upgrade Icon
-0,28 -3,26% 8,31 20:46:45
Preço de Abertura Preço Mínimo Preço Máximo Fech. Hoje Fech. Anterior
8,59 8,36 8,85 8,47 8,59
mais cotações »

Notícias Recentes

Data Hora Fonte Título
10/04/202409:00GLOBEArcutis Appoints David Topper as Chief Financial Officer
05/04/202417:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
01/04/202408:00GLOBESol-Gel’s Collaboration Partner First-to-File ANDA Drug..
28/03/202409:00GLOBEArcutis to Present at the 23rd Annual Needham Virtual..
11/03/202409:00GLOBEArcutis Promotes Todd Tucker to Chief Human Resources..
10/03/202417:00GLOBEArcutis Presents Late-Breaking Data From INTEGUMENT-PED..
09/03/202418:00GLOBENew Research Reveals Genomic Profile of Seborrheic..
05/03/202418:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
04/03/202418:00GLOBEArcutis Announces Closing of Public Offering of Common Stock..
04/03/202410:00GLOBEArcutis Announces Acceptance of Late Breaking Abstract in..
29/02/202419:00GLOBEArcutis to Present at the TD Cowen 44th Annual Health Care..
29/02/202401:30GLOBEArcutis Announces Pricing of $150 Million Public Offering
28/02/202418:10GLOBEArcutis Announces Proposed Public Offering
28/02/202418:00GLOBEArcutis and Sato Announce Strategic Collaboration and..
27/02/202407:50GLOBEArcutis Announces Fourth Quarter and Full Year 2023..
16/02/202410:00GLOBEArcutis to Report Fourth Quarter and Full Year 2023..
06/02/202418:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
31/01/202410:00GLOBEArcutis to Present at the Guggenheim Healthcare Talks – 6th..
29/01/202410:00GLOBEJournal of the American Academy of Dermatology Publishes..
22/01/202410:00GLOBEZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment..
14/01/202406:00GLOBEZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic..
15/12/202320:13DJNArcutis Biotherapeutics Shares Jump After FDA OKs..
15/12/202319:49DJNArcutis Biotherapeutics' Application for Seborrheic..
15/12/202319:11GLOBEFDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam,..
02/12/202300:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
29/11/202310:00GLOBEFDA Accepts Arcutis’ Supplemental New Drug Application for..
03/11/202308:30GLOBEArcutis Announces Third Quarter 2023 Financial Results and..
02/11/202317:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
25/10/202317:00GLOBEArcutis to Report Third Quarter 2023 Financial Results
20/10/202309:00GLOBENew Data Shows ZORYVE® (Roflumilast) Cream 0.3% Provided..
20/10/202300:45GLOBEArcutis Announces Pricing of $100 Million Public Offering
19/10/202317:04GLOBEArcutis Announces Proposed Public Offering
13/10/202309:00GLOBEArcutis Presents Positive Patient-Reported Outcome Data from..
06/10/202309:52DJNArcutis Biotherapeutics Shares Rise Premarket As FDA OKs..
06/10/202309:00GLOBEFDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for..
05/10/202317:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
27/09/202309:00GLOBEArcutis Appoints L. Todd Edwards as Chief Commercial Officer
25/09/202310:00GLOBENew Campaign from Arcutis Aims to Educate, Raise Awareness,..
19/09/202308:30GLOBEArcutis Announces Positive Results from INTEGUMENT-PED..
15/09/202317:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
12/09/202308:30GLOBEArcutis Submits Roflumilast Cream 0.15% Supplemental New..
07/09/202309:15GLOBEArcutis Announces Positive Long-Term Results of Roflumilast..
05/09/202317:00GLOBEArcutis to Present at Upcoming Investor Conference
31/08/202309:00GLOBEArcutis Biotherapeutics Publishes Annual Environmental,..
29/08/202309:00GLOBEArcutis Launches First Television Ad for ZORYVE®..
18/08/202317:30GLOBEArcutis Appoints Interim Chief Financial Officer (CFO)
10/08/202309:16GLOBEArcutis and Huadong Announce Strategic Collaboration and..
08/08/202317:02GLOBEArcutis Announces Second Quarter 2023 Financial Results and..
04/08/202317:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
24/07/202317:00GLOBEArcutis to Report Second Quarter Financial Results

Seu Histórico Recente

NASDAQ
ARQT
Arcutis Biotherapeutics
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados